- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07356973
Irinotekan-ChemoSeed vid kirurgiskt resektabelt glioblastom (OPTICAL)
Öppen etikett Fas 2 säkerhets- och effektstudie av Irinotekan-ChemoSeed administrerat direkt in i resektionsmarginalen hos patienter med kirurgiskt resektabelt glioblastom
Part 1 (dose escalation, safety, and preliminary efficacy) Part 1 is a non-randomised, single-arm design in 12 participants with recurrent GBM suitable for maximal safe surgical resection.
Part 1 will evaluate safety, determine the MTD of irinotecan-ChemoSeed and the RP2D (corresponding to coverage of as much of the resection cavity as possible, up to the MTD) and evaluate efficacy. All Part 1 participants will be administered irinotecan- ChemoSeed concurrent to Standard of Care (SoC) treatment. Part 1 dose- escalation will start at 72 mg of IRN Part 2, in 135 participants with newly diagnosed GBM suitable for maximal safe surgical resection, will assess the efficacy of irinotecan-ChemoSeed. The actual number of irinotecan-ChemoSeeds administered into the resected tumour margin of the tumour cavity after surgical resection will be at the discretion of the neurosurgical consultant up to the MTD, to cover as much of the resection cavity as possible. Participants will be randomised in a 2:1 ratio:
- Arm 1: Irinotecan-ChemoSeed +SoC: Irinotecan-Chemoseeds administered into the resection margin following maximal safe surgical resection, with fractionated RT, concomitant and maintenance TMZ (based on Stupp protocol) starting 4 to 6 weeks after surgery per institution standard practice.
- Arm 2: SoC treatment only: maximal safe surgical resection with fractionated RT, concomitant and maintenance TMZ (based on Stupp protocol) starting 4 to 6 weeks after surgery per institution standard practice.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Chris McConville, Pr
- Telefonnummer: +44 (0) 78342 67819
- E-post: chrismcconville@extrudedpharmaceuticals.com
Studieorter
-
-
-
Birmingham, Storbritannien, B15 2TH
- Rekrytering
- University Hospitals Birmingham NHS Foundation Trust
-
Kontakt:
- Athanasios Zisakis, Dr
- Telefonnummer: 0044 7729463756
- E-post: Athanasios.Zisakis@uhb.nhs.uk
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
1. Radiologically relapsed, neuropathologically verified GBM (by the WHO 2021 criteria) (Part 1) or newly diagnosed, radiologically suspected GBM (Part 2) amenable to surgical resection.
2. Male or female aged 18 years or older. 3. Ability to understand and the willingness to sign a written informed consent form (ICF).
4. KPS ≥ 70. 5. Life expectancy ≥ 6 months. 6. Adequate organ and marrow function as follows (all required):
-
Absolute neutrophil count ≥ 1.5 k/µL
-
Platelets ≥ 100 k/µL
-
Haemoglobin ≥ 9 g/dL
-
Serum creatinine ≤ 1.8 mg/dL or creatinine clearance > 50 mL/min
-
Bilirubin ≤ 1.5 mg/dL
-
Alanine aminotransferase (ALT) ≤ 3.0 × upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) ≤ 3.0 × ULN
-
Prothrombin time ≤ 1.5 × ULN
-
International normalised ratio (INR) ≤ 1.5 × ULN
-
Partial thromboplastin time ≤ 1.5 × ULN 7. Women of childbearing potential must agree to use a highly effective method of contraception for the duration of the trial or for 5X the systemic half-life (i.e., 6 weeks) plus 6 months following irinotecan-ChemoSeed administration, whichever is the longest.. Female participants must refrain from egg donation during the same time period. 8. Male participants of reproductive potential, who intend to be sexually active with a female partner of childbearing potential, must commit to use barrier contraception (e.g., condom) for the duration of the trial or for 5X the systemic half-life (i.e., 6 weeks) plus 6 months following irinotecan-ChemoSeed administration, whichever is the longest. Male participants must not donate or bank sperm during the same time period.
Exclusion Criteria:
-
-
1. Multicentric disease defined by tumours which have multiple discrete areas of contrast enhancing or non-enhancing tumour without connecting T2/ fluid-attenuated inversion recovery (FLAIR) signal abnormality. 2. Diffuse leptomeningeal disease. 3. Not eligible for surgical resection. 4. Known hypersensitivity to IRN or PLGA. 5. Prior IRN treatment (for Part 2 participants) less than 12 months from trial enrolment 6. Pregnant or lactating women or participants who intend to get pregnant during the trial.
7. Prior active malignancy except for non-melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 3 years prior to surgical resection and trial drug administration. 8. Part 1 participants with relapsed GBM: treatment with another investigational drug or other intervention within 4 weeks prior to the surgical resection or 5 times the half-life (whichever is longer) before trial drug administration. 9. Part 2 participants with newly diagnosed GBM: prior RT, chemotherapy, immunotherapy, or targeted agents administered specifically for the lesion being treated.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Dose Determination (Part 1)
Dose escalation to identify maximum tolerance dose MTD |
irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM |
|
Övrig: Efficacy Testing (Part 2)
2 : 1 randomization irinotecan-ChemoSeed versus standard of care |
irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Del 1 Att bestämma den optimala dosen av Irinotecan (RP2D) som ska administreras för Del 2.
Tidsram: 13 månader
|
13 månader
|
|
|
Part 2. Determination Of Progression Free Survival (PFS) to demonstrate the superiority of irinotecan-ChemoSeed compared to concurrent to SoC treatment
Tidsram: 39 months
|
To demonstrate superiority of irinotecan-ChemoSeed concurrent to SoC treatment and administered into the resection margin following maximal safe surgical resection relative to SoC treatment alone, by assessment of progression-free survival (PFS). |
39 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Response Rate (ORR)
Tidsram: 6 months from recruitment
|
ORR at 6 months by MRI using RANO 2.0 criteria, by independent central review and by investigator assessment. |
6 months from recruitment
|
|
Disease Control Rate (DCR)
Tidsram: 12 months from recruitment
|
DCR at 12 months by MRI using RANO 2.0 by independent central review and investigator assessment. |
12 months from recruitment
|
|
Overall Survival
Tidsram: 39 months
|
Comparison of Median OS for control and treated arms |
39 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Garth S Cruickshank, MBBS, PhD, Emeritus Professor of Neurosurgery, University of Birmingham UK
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ICS1
- IRAS ID: 1012556 (Registeridentifierare: Regulatory Agency Identifier)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .